Rexgenero company

Rexgenero is a leading regenerative medicine company and developer of advanced cell-based therapeutics for the treatment of serious diseases that are poorly treated with existing therapies. They are conducting clinical trials with their cellular therapies with the intention of obtaining marketing authorization in Europe, the United States and other markets. Their treatments draw on an exceptional understanding of the fundamental science of cell therapies. Their current cell therapies have been developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies and they aim to work with them to develop further cell therapies to treat other indications with high unmet medical needs.
Technology: P4 Medicine
Industry: Regenerative Medicine
Headquarters: London, England, United Kingdom
Founded Date: Undisclosed
Employees Number: Undisclosed
Funding Status: Early Stage Venture
Investors Number: 2
Total Funding: $18.7M
Estimated Revenue: $10M to $50M
Last Funding Type: Grant

Visit Website
Register and Claim Ownership